Posters

Functional γδ T cells in genO-BRGSF-HIS mice

γδ T cells in genO-BRGSF-HIS

Preclinical double humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies

Humanized mice for anti-CD47/SIRPα-targeting therapies

Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice

TME composition in genO-BRGSF-HIS mice

(Seismic) Discovery and characterization of a novel engineered Fc-fused IgE cleaving enzyme for treatment of IgE mediated diseases

Allergic and atopic diseases with genO-hIgE/hFcεRI

(Evotec) Modeling Inflammatory Bowel Disease in mice with “Humanized” immune system

Inflammatory bowel disease with genO-BRGSF-HIS

Mar 2025

(AstraZeneca) AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens

T-cell engager assessment with Pan hCD3

(Anaveon) ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4 + and CD8 + tumor specific T cells by acting in the tumor microenvironment and draining lymph nodes

Anti-tumor efficacy with hPD-1

(Anaveon) ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells

Efficacy assessment with hPD-1

(Teva Pharmaceuticals) Preclinical in vivo characterization of the anti-tumor activity of a non-blocking PD-1 antibody fused to attenuated IL-2

Anti-tumor immunotherapy

FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies

hFcγR mice for therapeutic antibody assessment

Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice

TME composition in BRGSF-HIS mice

Assessment of γδ T-cell therapies in humanized mice

BRGSF-HIS for γδ T-cell therapies

BRGSF-HIS mice as a predictive tool for safety assessment of biologics

BRGSF-HIS for safety assessment

Sep 2024

(Macomics) Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy

In vivo tumor growth suppression

(Sensei) Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

CD28xVISTA bispecific antibodies in immunotherapy

(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells

Safety and activity of a conditionally active cLAG3-IL2

(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Multispecific CD73/PD-1 targeting

Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies

FcγR mouse models for efficacy and PK/PD

CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies

CD28-targeting therapies

Novel TFRC humanized mouse model for drug delivery to the brain

Drug delivery to the brain (TFRC)

Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice

BRGSF-HIS & tumor microenvironment

(Crescendo) CB307: A dual targeting costimulatory Humabody ® VH therapeutic for treating PSMA-positive tumors

Half-life extended bispecific costimulatory antibody

Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model

BRGSF-HIS & myeloid cell compartment in CRS

Cell-depleting agents assessment in preclinical models

BRGSF-HIS & hFcγR to assess cell depletion

(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

CD3 binding T-cell engagement

(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

(VIB) A Cross-Species Map and Humanized Mouse Model of Fcγ Receptors and FcRn

Humanized Mouse Model of Fcγ Receptors

Sep 2023

(Reaction Biology) Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics

hPD-1 to evaluate novel cancer therapies

(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells

PD-1 & strong tumor growth inhibition

(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model

CTLA-4 & survival in a colorectal cancer model

Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment

BRGSF-HIS for myeloid-directed therapy assessment